Literature DB >> 14617588

NOS inhibitors exhibit antinociceptive properties in the rat formalin test.

Marie-Françoise Doursout1, Yangyan Liang, Jacques E Chelly.   

Abstract

PURPOSE: To assess the systemic and nociceptive effects of nitric oxide synthase (NOS) inhibitors in the modulation of acute pain in rats subjected to the formalin test.
METHODS: Formalin 5% was injected in the hind paw in the presence and absence of NOS inhibitors (e.g., 7-nitro indazole, N-nitro-L-arginine and aminoguanidine). Catheters were chronically implanted to continuously record mean arterial blood pressure (MAP) and heart rate (HR). MAP, HR and paw lifting time were recorded at control and every five minutes for 35 min following formalin and NOS inhibitors.
RESULTS: Formalin injected into the rat hind paw induced a biphasic nociceptive behaviour: an initial acute phase (phase 1: during zero to five minutes after the formalin injection) followed by a prolonged tonic response (phase 2: beginning about ten minutes after the formalin injection). Aminoguanidine, an inhibitor of the inducible NOS and 7-nitro indazole, an inhibitor of the neuronal NOS, did not affect phase 1, whereas N-nitro-L-arginine, a non-selective NOS inhibitor decreased it (49%). All three NOS inhibitors diminished nociceptive behaviours during phase 2. L-arginine reversed antinociceptive effects of N-nitro-L-arginine in phase 1 and in phase 2. Pressor effects induced by formalin in phase 1 were abolished following all three NOS inhibitors. During phase 2, formalin-induced pressor effects remained unaffected by N-nitro-L-arginine and aminoguanidine but were inhibited by 7-nitro indazole.
CONCLUSION: Our data demonstrate that NO is predominantly generated by vascular endothelial NOS in phase 1 and phase 2, whereas the neuronal NOS and the inducible NOS exhibit antinociceptive effects through a non-NO related pathway in phases 1 and 2 in rats subjected to the formalin test.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617588     DOI: 10.1007/BF03018738

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  6 in total

1.  Effects of hyperbaric oxygen on pain-related behaviors and nitric oxide synthase in a rat model of neuropathic pain.

Authors:  Guang Han; Lu Li; Ling-Xin Meng
Journal:  Pain Res Manag       Date:  2013 May-Jun       Impact factor: 3.037

2.  Nitric oxide is negatively correlated to pain during acute inflammation.

Authors:  May Hamza; Xiao-Min Wang; Tongtong Wu; Jaime S Brahim; Janet S Rowan; Raymond A Dionne
Journal:  Mol Pain       Date:  2010-09-15       Impact factor: 3.395

3.  Antinociceptive effects of (O-methyl)-N-benzoyl tyramine (riparin I) from Aniba riparia (Nees) Mez (Lauraceae) in mice.

Authors:  F L O Araújo; C T V Melo; N F M Rocha; B A Moura; C P Leite; J F Amaral; J M Barbosa-Filho; S J C Gutierrez; S M M Vasconcelos; G S B Viana; Francisca Cléa Florenço de Sousa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-06-26       Impact factor: 3.000

4.  Reduced spinal microglial activation and neuropathic pain after nerve injury in mice lacking all three nitric oxide synthases.

Authors:  Kazuya Kuboyama; Makoto Tsuda; Masato Tsutsui; Yumiko Toyohara; Hidetoshi Tozaki-Saitoh; Hiroaki Shimokawa; Nobuyuki Yanagihara; Kazuhide Inoue
Journal:  Mol Pain       Date:  2011-07-14       Impact factor: 3.395

5.  Antinociceptive effect of geranylgeraniol and 6alpha,7beta-dihydroxyvouacapan-17beta-oate methyl ester isolated from Pterodon pubescens Benth.

Authors:  Humberto M Spindola; Leila Servat; Carina Denny; Rodney A F Rodrigues; Marcos N Eberlin; Elaine Cabral; Ilza M O Sousa; Jorge Y Tamashiro; João E Carvalho; Mary A Foglio
Journal:  BMC Pharmacol       Date:  2010-01-07

6.  Norepinephrine-induced nociception and vasoconstrictor hypersensitivity in rats with chronic post-ischemia pain.

Authors:  Dimitris N Xanthos; Gary J Bennett; Terence J Coderre
Journal:  Pain       Date:  2008-01-14       Impact factor: 7.926

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.